Novel strategy for vaping cessation among youth
A novel treatment approach could help youth achieve vaping cessation.
In a study published in JAMA, researchers randomly assigned 261 treatment-seeking participants aged 16 to 25 years to undergo treatment with varenicline in addition to weekly behavioral counseling and vaping cessation support, placebo in addition to weekly behavioral counseling, or usual care in addition to vaping cessation support.
The researchers found that compared with those in the placebo or usual care groups, the participants in the varenicline group achieved greater continuous vaping abstinence and lower nicotine withdrawal symptoms. Varenicline was also found to be generally well tolerated, with a comparable rate of treatment-emergent adverse events compared with the other two treatment groups.
The results of the study represented the potential of a pharmacologic approach to treat vaping among younger individuals.
Read more: JAMA
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.